drugset
drugset / Trial / NCT02251951

Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer

NCT02251951 ↗

Phase 2 Completed 39 enrolled Hellenic Oncology Research Group
NaSingle-groupOpen-labelTreatment

Summary

The investigators propose to study the efficacy and safety of nab-Paclitaxel in a Phase II trial of patients with locally advanced or metastatic adenocarcinomas of the stomach and gastro-esophageal junction

Timeline

Start
2012-09
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Nab-paclitaxel Small molecule 150 mg/m2 Intravenous

Indications

gastroesophageal cancer